Scarica l'app Stockscreener
5.63
0.88%
-0.05
Dopo l'orario di chiusura:
5.75
0.12
+2.13%
Precedente Chiudi:
$5.68
Aprire:
$5.73
Volume 24 ore:
18,438
Relative Volume:
0.12
Capitalizzazione di mercato:
$3.27M
Reddito:
$644.60K
Utile/perdita netta:
$-9.87M
Rapporto P/E:
-0.00672
EPS:
-837.9618
Flusso di cassa netto:
$-9.02M
1 W Prestazione:
-15.47%
1M Prestazione:
+1.44%
6M Prestazione:
-80.92%
1 anno Prestazione:
-93.43%
Intervallo 1D:
$5.62
$5.895
Intervallo di 1 settimana:
$5.5406
$6.6589
Portata 52W:
$4.71
$220.25
Biodexa Pharmaceuticals Plc Adr Stock (BDRX) Company Profile
Nome
Biodexa Pharmaceuticals Plc Adr
Settore
Industria
Telefono
-
Indirizzo
-
Biodexa Pharmaceuticals Plc Adr Borsa (BDRX) Ultime notizie
Biodexa Pharmaceuticals Submits SEC Filing with Auditors’ Nod - TipRanks
BDRX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Biodexa Pharmaceuticals Plc and Encourages Investors to Contact the Firm - GlobeNewswire Inc.
Biodexa reports promising glioblastoma trial results - Investing.com
Biodexa Pharmaceuticals releases patient updates on PFS, OS from MAGIC-1 study - TipRanks
Biodexa's MX-110 Continues to Show Promise in Recurrent Glioblastoma (rGBM), the Deadliest Brain Cancer - StockTitan
Stock Surge: Biodexa Pharmaceuticals Plc ADR (BDRX) Closes at 5.01, Marking a -4.21 Increase/Decrease - The Dwinnex
Biodexa Pharmaceuticals Secures Nasdaq Compliance Extension - TipRanks
Biodexa secures Nasdaq listing extension - Investing.com
Biodexa Pharmaceuticals granted extension to regain compliance with Nasdaq - TipRanks
Biodexa secures Nasdaq listing extension By Investing.com - Investing.com UK
Biodexa Announces Successful Appeal of Nasdaq Delisting - StockTitan
Biodexa provides update on PFS, OS in Phase 1 study of MTX110 in rGBM - TipRanks
Biodexa reports survival rates in glioblastoma study - Investing.com India
Biodexa reports updated Phase 1 data from glioblastoma study (NASDAQ:BDRX) - Seeking Alpha
Biodexa’s MTX110 Shows Promise in Brain Cancer Study - TipRanks
Biodexa reports survival rates in glioblastoma study By Investing.com - Investing.com UK
Biodexa Provides Update on Progression Free and Overall Survival in Phase 1 Study of MTX110 in Recurrent Glioblastoma - StockTitan
Ratio Analysis: Unpacking Biodexa Pharmaceuticals Plc ADR (BDRX)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Biodexa Pharmaceuticals Plc ADR (BDRX) Stock: A Year of Declines and Increases - The InvestChronicle
Should investors be concerned about BDRX’s high price-to-sales ratio? - US Post News
Interim results for the six months ended June 30, 2024 - StockTitan
Biodexa Pharmaceuticals Reports Promising H1 2024 Results - TipRanks
Market Watch Highlights: Biodexa Pharmaceuticals Plc ADR (BDRX) Ends on an Downturn Note at 0.29 - The Dwinnex
Biodexa Pharmaceuticals announces ADR ratio change - Investing.com
ADR Ratio Change - Markets Insider
Biodexa Pharmaceuticals Announces ADR Ratio Change - TipRanks
Biodexa secures full access to cancer research grant - Investing.com
Biodexa Pharmaceuticals Advances FAP Treatment - TipRanks
BDRX Stock on the Rise: A Promising Investment - The InvestChronicle
Financial Health Report: Biodexa Pharmaceuticals Plc ADR (BDRX)’s Ratios Tell a Tale - The Dwinnex
Biodexa Pharmaceuticals Plc ADR (BDRX) produces promising results - US Post News
Investors in cash trouble should check out Biodexa Pharmaceuticals Plc ADR (BDRX) - SETE News
Receipt of Nasdaq Delisting DeterminationPlans to Appeal - StockTitan
Biodexa Pharmaceuticals Plc ADR (BDRX) is a good investment, but the stock may be undervalued - US Post News
Balance Sheet Breakdown: Biodexa Pharmaceuticals Plc ADR (BDRX)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex
Biodexa Pharmaceuticals sets $5 million offering - Investing.com
Financial Metrics Check: Biodexa Pharmaceuticals Plc ADR (BDRX)’s Ratios for Trailing Twelve Months - The Dwinnex
BDRX Stock Price and Chart — NASDAQ:BDRX - TradingView
Are Smart Investors Making the Right Decision? Biodexa Pharmaceuticals Plc ADR (BDRX) - SETE News
Biodexa’s Diabetes Drug Enters Phase 2a Studies - TipRanks
The time has not yet come to remove your chips from the table: Biodexa Pharmaceuticals Plc ADR (BDRX) - SETE News
Why Ericsson Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket - Benzinga
Why ConAgra Brands Shares Are Trading Lower? Here Are Other Stocks Moving In Thursday's Mid-Day Session - Benzinga
eRapa shows promise in Phase 2 for FAP treatment, Biodexa reveals - Investing.com
BDRX’s Stock Market Adventure: -73.47% YTD Growth Amidst Volatility - The InvestChronicle
Biodexa Announces Additional Positive Results Of Phase 2 Trial Of eRapa in Treatment Of Precancerous Polyps in the GI TractNow 12-Month Data - StockTitan
Midatech Pharma PLC Announces Posting of Annual Report & Notice of AGM - Quantisnow
Midatech Pharma PLC Announces Business Update - Quantisnow
Midatech Pharma PLC Announces Fast Track Designation for MTX110 Development - Quantisnow
Midatech Pharma PLC Announces IND Application for MTX110 Study in GBM Effective - Quantisnow
Midatech Pharma PLC Announces Receipt of NASDAQ Notification - Quantisnow
Biodexa Pharmaceuticals Plc Adr Azioni (BDRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.02%
0.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):